Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

67.16 -0.45 (-0.67%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know ↗

August 22, 2026

This filing details a non-discretionary sale that reduced Lefkofsky's direct holdings by a small percentage.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

AI Found an Influenza Target That Survives Viral Mutation

August 10, 2026

Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)

From Equity Insider

Via GlobeNewswire

Why Is Tempus AI Stock Surging on Friday? ↗

August 07, 2026

Tempus AI Inc. (NASDAQ: TEM) stock jumped on Friday, August 7, 2026, following strong AI healthcare peer earnings from Doximity Inc. and a strategic lab expansion with CellCarta.

Via Benzinga

Topics Artificial Intelligence

Tempus AI (NASDAQ:TEM) Delivers Mixed Q2 Results with EPS Beat, Stock Slips in After-Hours Trading ↗

July 30, 2026

Via Chartmill

Topics Artificial Intelligence

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

August 04, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus AI Q2 Earnings Call Highlights ↗

July 31, 2026

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial...

Via MarketBeat

Topics Artificial Intelligence Earnings

Tempus AI Stock Slides Friday: What's Driving the Post-Earnings Reset? ↗

July 31, 2026

Tempus AI Inc. (NASDAQ: TEM) shares are trading lower Friday as traders digest post-earnings reset in expectations.

Via Benzinga

Topics Artificial Intelligence

Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares? ↗

July 31, 2026

Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus Reports Second Quarter 2026 Results

July 30, 2026

From Tempus AI, Inc.

Via Business Wire

3 Powerful AI Stocks Poised for the Next Massive Shift ↗

July 28, 2026

AI's next winners may emerge from an overlooked part of the market. See how three software companies are turning proprietary expertise into a potentially powerful growth engine.

Via The Motley Fool

Topics Artificial Intelligence

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

July 22, 2026

From Tempus AI, Inc

Via Business Wire

Tempus AI Bets on MRD Testing Growth With Personalis Acquisition ↗

July 20, 2026

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma...

Via MarketBeat

Topics Artificial Intelligence

Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service

July 16, 2026

From Tempus

Via Business Wire

Tempus to Report Second Quarter 2026 Financial Results on July 30

July 09, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

June 25, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

June 11, 2026

From Tempus AI, Inc.

Via Business Wire

Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

June 09, 2026

From Ambry Genetics

Via Business Wire

Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner ↗

June 08, 2026

Tempus AI is growing fast, but the real debate is whether its healthcare data platform can justify the premium price investors are already paying.

Via The Motley Fool

Topics Artificial Intelligence

Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 05, 2026

From Tempus AI, Inc.

Via Business Wire

Why Tempus AI Stock Is Surging On Thursday? ↗

June 04, 2026

Tempus AI (NASDAQ: TEM) stock is surging Thursday after launching a first-of-its-kind open-source digital pathology consortium with Yale New Haven Health and MSK.

Via Benzinga

Topics Artificial Intelligence

Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

June 03, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

June 01, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

May 31, 2026

From Tempus AI, Inc.

Via Business Wire

What to Know About This Fund's $32.6 Million Porch Group Purchase ↗

May 30, 2026

This technology-driven firm delivers software and insurance solutions for home services professionals, homebuyers, and homeowners.

Via The Motley Fool

Topics Regulatory Compliance

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

May 30, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

May 30, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

May 29, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

May 29, 2026

From Tempus AI, Inc.

Via Business Wire

Why Is Tempus AI Stock Surging On Thursday? ↗

May 28, 2026

Discover why Tempus AI Inc (NASDAQ:TEM) stock is surging today following major platform expansions and landmark clinical data ahead of ASCO 2026.

Via Benzinga

Topics Artificial Intelligence

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

May 28, 2026

The widely followed growth investor keeps making moves.

Via The Motley Fool

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.